Ishare Nq Biotch ETF (IBB) 271.13 $IBB
SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 1.64% Gain
Comtex SmarTrend(R) - Fri Jul 01, 12:29PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $256.53 to a high of $263.47. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $257.88 on volume of 688,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 271.13 (+3.29)
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 1.64% Rise
Comtex SmarTrend(R) - Fri Jul 01, 12:27PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $256.53 to a high of $263.47. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $257.88 on volume of 688,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 271.13 (+3.29)
Top and Flop ETFs of 1H
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 10:28AM CDT
Inside the best and worst performing ETFs of 2016.
DXJF: 15.82 (+0.02), PBE: 39.33 (+0.55), IBB: 271.13 (+3.29), KOL: 9.61 (+0.30), TAN: 21.44 (+0.47), SILJ: 16.83 (+0.92), EPU: 32.09 (+0.71), RING: 12.99 (+0.34), BBC: 19.28 (+0.27), GLDX: 42.76 (+0.14), GDXJ: 49.41 (+2.29), TAPR: 14.95 (-0.57), SGDM: 28.70 (+0.86), BUNL: 39.75 (unch)
Vista Partners Initiates Coverage on Mount TAM Biotechnologies, Inc. (Ticker: MNTM); $3.25 Price Target
Marketwired - Thu Jun 30, 8:00AM CDT
SAN FRANCISCO, CA--(Marketwired - Jun 30, 2016) - Vista Partners announced today that it has initiated coverage on Mount TAM Biotechnologies, Inc. (OTCBB: MNTM) ("The Company," or "MNTM"
with a twelve-month price target of $3.25. Ross Silver, Principal Analyst at Vista Partners, stated, "Mount Tam's first and most advanced product (TAM-01), was acquired through a licensing agreement with The Buck Institute for Research on Aging. TAM-01 is intended for the treatment of systemic lupus erythematosus ("SLE", the most common form of lupus and is the Company's lead compound." Mr. Silver concludes, "According to the Lupus Foundation of America, 1.5 million Americans have some form of lupus and more than 16,000 new cases are reported annually in the United States alone, while other estimates are more conservative. TAM-01 is a small molecule that in preclinical animal models has shown the potential to be disease modifying and has the potential to treat lupus nephritis, as a reminder 60% of SLE patients have lupus nephritis."
IBB: 271.13 (+3.29)
Brexit: A Bane for Bumbling Biotech ETFs?
editor@etftrends.com (ETF Trends) - ETF Trends - Tue Jun 28, 9:53AM CDT
Brexit is the excuse of the moment that many market observers are pointing to explain the near-term struggles of various asset classes and sectors. In some cases, that observation is accurate. In others, it lacks merit. If there is a silver lining,...
IBB: 271.13 (+3.29)
After Yesterday's Decline of 2.08%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 27, 12:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $240.86 to a high of $249.21. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $248.83 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 2.08% Yesterday
Comtex SmarTrend(R) - Mon Jun 27, 12:05PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $240.86 to a high of $249.21. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $248.83 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.80%
Comtex SmarTrend(R) - Tue Jun 21, 12:19PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.86 to a high of $259.50. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $256.34 on volume of 785,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
Vista Partners Publishes June 2016 Macroeconomic & Investment Newsletter
Marketwire Canada - Tue Jun 21, 8:01AM CDT
Topics Include: Monthly Macroeconomic Commentary, Investment Considerations, Big Data, Biotechnology, Fintech, Healthcare, IoT, SaaS, Sports, WearableTech & More
IBB: 271.13 (+3.29), IMNP: 0.40 (+0.01)
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Rebound after Yesterday's 1.20% Sell Off
Comtex SmarTrend(R) - Fri Jun 17, 12:13PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $257.55 to a high of $262.99. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $258.19 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
After Yesterday's Decline of 1.11%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 13, 12:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $264.04 to a high of $269.98. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $266.20 on volume of 893,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), ALXN: 124.42 (+1.08), IBB: 271.13 (+3.29), REGN: 378.35 (+6.90)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), SRPT: 22.62 (+1.70), ALXN: 124.42 (+1.08), IBB: 271.13 (+3.29), REGN: 378.35 (+6.90)
A Catalyst for Biotech ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Jun 06, 7:00AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotechnology exchange traded fund, is up 9.2% over the past month. Performances for some rival biotech ETFs have been even better and that may be setting the stage for once beloved...
FBT: 93.72 (+0.78), XBI: 57.59 (+0.52), IBB: 271.13 (+3.29)
SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 1.64% Gain
Comtex SmarTrend(R) - Fri Jul 01, 12:29PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $256.53 to a high of $263.47. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $257.88 on volume of 688,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 271.13 (+3.29)
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 1.64% Rise
Comtex SmarTrend(R) - Fri Jul 01, 12:27PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $256.53 to a high of $263.47. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $257.88 on volume of 688,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 271.13 (+3.29)
Top and Flop ETFs of 1H
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 10:28AM CDT
Inside the best and worst performing ETFs of 2016.
DXJF: 15.82 (+0.02), PBE: 39.33 (+0.55), IBB: 271.13 (+3.29), KOL: 9.61 (+0.30), TAN: 21.44 (+0.47), SILJ: 16.83 (+0.92), EPU: 32.09 (+0.71), RING: 12.99 (+0.34), BBC: 19.28 (+0.27), GLDX: 42.76 (+0.14), GDXJ: 49.41 (+2.29), TAPR: 14.95 (-0.57), SGDM: 28.70 (+0.86), BUNL: 39.75 (unch)
Vista Partners Initiates Coverage on Mount TAM Biotechnologies, Inc. (Ticker: MNTM); $3.25 Price Target
Marketwired - Thu Jun 30, 8:00AM CDT
SAN FRANCISCO, CA--(Marketwired - Jun 30, 2016) - Vista Partners announced today that it has initiated coverage on Mount TAM Biotechnologies, Inc. (OTCBB: MNTM) ("The Company," or "MNTM"
with a twelve-month price target of $3.25. Ross Silver, Principal Analyst at Vista Partners, stated, "Mount Tam's first and most advanced product (TAM-01), was acquired through a licensing agreement with The Buck Institute for Research on Aging. TAM-01 is intended for the treatment of systemic lupus erythematosus ("SLE", the most common form of lupus and is the Company's lead compound." Mr. Silver concludes, "According to the Lupus Foundation of America, 1.5 million Americans have some form of lupus and more than 16,000 new cases are reported annually in the United States alone, while other estimates are more conservative. TAM-01 is a small molecule that in preclinical animal models has shown the potential to be disease modifying and has the potential to treat lupus nephritis, as a reminder 60% of SLE patients have lupus nephritis." IBB: 271.13 (+3.29)
Brexit: A Bane for Bumbling Biotech ETFs?
editor@etftrends.com (ETF Trends) - ETF Trends - Tue Jun 28, 9:53AM CDT
Brexit is the excuse of the moment that many market observers are pointing to explain the near-term struggles of various asset classes and sectors. In some cases, that observation is accurate. In others, it lacks merit. If there is a silver lining,...
IBB: 271.13 (+3.29)
After Yesterday's Decline of 2.08%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 27, 12:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $240.86 to a high of $249.21. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $248.83 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 2.08% Yesterday
Comtex SmarTrend(R) - Mon Jun 27, 12:05PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $240.86 to a high of $249.21. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $248.83 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.80%
Comtex SmarTrend(R) - Tue Jun 21, 12:19PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.86 to a high of $259.50. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $256.34 on volume of 785,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
Vista Partners Publishes June 2016 Macroeconomic & Investment Newsletter
Marketwire Canada - Tue Jun 21, 8:01AM CDT
Topics Include: Monthly Macroeconomic Commentary, Investment Considerations, Big Data, Biotechnology, Fintech, Healthcare, IoT, SaaS, Sports, WearableTech & More
IBB: 271.13 (+3.29), IMNP: 0.40 (+0.01)
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Rebound after Yesterday's 1.20% Sell Off
Comtex SmarTrend(R) - Fri Jun 17, 12:13PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $257.55 to a high of $262.99. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $258.19 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
After Yesterday's Decline of 1.11%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 13, 12:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $264.04 to a high of $269.98. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $266.20 on volume of 893,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 271.13 (+3.29)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), ALXN: 124.42 (+1.08), IBB: 271.13 (+3.29), REGN: 378.35 (+6.90)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), SRPT: 22.62 (+1.70), ALXN: 124.42 (+1.08), IBB: 271.13 (+3.29), REGN: 378.35 (+6.90)
A Catalyst for Biotech ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Jun 06, 7:00AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotechnology exchange traded fund, is up 9.2% over the past month. Performances for some rival biotech ETFs have been even better and that may be setting the stage for once beloved...
FBT: 93.72 (+0.78), XBI: 57.59 (+0.52), IBB: 271.13 (+3.29)
